Safety of Intravitreal Injection of Biosimilar of Aflibercept in Rabbit Eyes

Table 2

The amplitudes and latent times of ERG waves from the biosimilar aflibercept-treated rabbits.

Groups	a-wave amplitude	b-wave amplitude	a-wave latent time	b-wave latent time
48 hours
Pretreatment	−50.4 ± 9.6	155.6 ± 30.1	13.1 ± 0.5	36.1 ± 0.5
Posttreatment	−48.9 ± 20.3	158.6 ± 64.5	14.6 ± 0.6	37.7 ± 1.7
Difference in %	Decrease 3%	Increase 1.9%	Increase 11.4%	Increase 4.4%
1 week
Pretreatment	−50.4 ± 9.7	158.9 ± 24.7	14.1 ± 0.7	36.5 ± 0.6
Posttreatment	−46.4 ± 9.9	151.4 ± 32.7	14.3 ± 0.8	36 ± 1.3
Difference in %	Decrease 8%	Decrease 4.8%	Increase 1.4%	Decrease 1.4%
2 weeks
Pretreatment	−44.3 ± 9.6	148.6 ± 27.4	14.1 ± 0.5	36.4 ± 0.8
Posttreatment	−37.8 ± 10.1	133.2 ± 40.2	14.4 ± 1.1	35.8 ± 1.4
Difference in %	Decrease 14.6%	Decrease 10.3%	Increase 2.1%	Decrease 1.7%
4 weeks
Pretreatment	−43 ± 8.7	154.9 ± 28.8	14.1 ± 0.6	36.7 ± 0.7
Posttreatment	−38.4 ± 20.5	140.9 ± 89.6	15.4 ± 1.1	40.2 ± 2.2
Difference in %	Decrease 10.7%	Decrease 9.1%	Increase 9.2%	Increase 9.5%

Data are mean ± SD.